Navigation Links
Stephen Zaniboni Joins Trovagene, Inc. as Chief Financial Officer
Date:2/10/2012

d technology for the detection of transrenal DNA and RNA, short nucleic acid fragments, originating from normal and diseased cell death that cross the kidney barrier and can be detected in urine.

Trovagene has a dominant patent position as it relates to transrenal molecular testing. It has U.S. and European patent applications and issued patents that cover testing for HPV and other infectious diseases, cancer, transplantation, prenatal and genetic testing. In addition, it owns worldwide rights to nucleophosmin-1 (NPM1), an informative biomarker for acute myeloid leukemia (AML) and mutations in the sf3b1 gene, which have been shown to be associated with chemotherapy response in CLL (chronic lymphocytic leukemia) patients.

Trovagene has filed a Form 10 with the SEC. More complete current information about Trovagene is contained in the filing.

Certain statements in this press release are forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995. These statements may be identified by the use of forward-looking words such as "anticipate," "believe," "forecast," "estimated" and "intend," among others. These forward-looking statements are based on Trovagene's current expectations and actual results could differ materially. There are a number of factors that could cause actual events to differ materially from those indicated by such forward-looking statements. These factors include, but are not limited to, substantial competition; our ability to continue as a going concern; our need for additional financing; uncertainties of patent protection and litigation; uncertainties of government or third party payer reimbursement; limited sales and marketing efforts and dependence upon third parties; and risks related to failure to obtain FDA clearances or approvals and noncompliance with FDA regulations. As with any medical diagnostic tests under development, there are significant risks in the development, regulatory approval and
'/>"/>

SOURCE Trovagene, Inc.
Copyright©2010 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related biology news :

1. Call Stephen Michnick a gene grammarian
2. American Society for Microbiology honors J. Stephen Dumler
3. Stephen Maturo, M.D., ear, nose and throat specialist, receives Charles Ferguson Award
4. 2011 Stephen H. Schneider Symposium
5. FSU joins coalition working to improve nations power grid
6. GEN joins Charles Darwin 2009 celebration
7. Genomatix joins Illumina-Connect program
8. Internationally acclaimed researcher joins UH faculty thanks to $5.5 million grant
9. Mycotoxin Research joins Springers life sciences journals program
10. Anatomical Science International joins Springers publishing program
11. DEIMOS joins MARS and its satellite of instruments on seafloor
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/21/2013)... , Where? Copenhagen, Denmark: Bella Center Congress ... , Why? An annual meeting ... developments, manufacturing and installation, drawing on leading experiences from ... edition from a record of more than 900 abstracts ... plenary and oral presentations, more than 460 visual presentation, ...
(Date:5/21/2013)... May 21, 2013 Royal Philips Electronics (NYSE: ... world,s first portable ultrasound with Philips, industry leading Live ... The CX50 xMATRIX with available Live 3D TEE and ... at the EuroPCR, official meeting for the European ... Since its launch in 2012, Philips CX50 xMATRIX ...
(Date:5/20/2013)... the antibiotic colistin are also commonly resistant to ... to a study in mBio , the ... Microbiology. Cross-resistance to colistin and host antimicrobials LL-37 ... bacterial attack, could mean that patients with life-threatening ... crippled immune response. Colistin is a last-line drug ...
Breaking Biology News(10 mins):21st European Biomass Conference and Exhibition 221st European Biomass Conference and Exhibition 321st European Biomass Conference and Exhibition 4Philips CX50 xMATRIX now offers world-class interventional and diagnostic features on single portable system 2Resistance to last-line antibiotic makes bacteria resistant to immune system 2Resistance to last-line antibiotic makes bacteria resistant to immune system 3
... FASEB Journal provide more evidence that if we ... improve. According to MIT scientists, dietary nutrients found in ... eggs increase brain synapses and improve cognitive abilities. ... animals, respond to this kind of treatment by making ...
... State University faculty member who uses computational techniques ... is attracting worldwide attention from other researchers. ... and biomedical engineering at the Florida A&M University-Florida ... computers to determine how substances known as recombinant ...
... alarmed by the dramatic decline of at least 30 percent ... Nepal, once a refuge that boasted among the highest densities ... survey of April 2008 showed a population of between 6-14 ... Government of Nepal made a low-key announcement on July 1 ...
Cached Biology News:FSU researcher using computers to hone cancer-fighting strategies 2Tigers disappear from Himalayan refuge 2
(Date:5/22/2013)... FL (PRWEB) May 22, 2013 A recent ... of probiotics on athletes to find that those who took ... longer. The results from the study showed that in extreme ... Action, known for their adult acne treatment explains ... and how it may help their skin condition. , ...
(Date:5/22/2013)... Mass. , May 22, 2013  Moderna Therapeutics, ... new treatment modality to enable the in vivo ... John Reynders will join Moderna in ... Reynders is a proven leader in the ... of drug development, from discovery to translation, clinical operations ...
(Date:5/21/2013)... BEACH, Fla. , May 21, 2013 /PRNewswire/ ... FCN ), the global business advisory ... their enterprise value (the "Company"), announced that it ... personnel that were formerly included within the Corporate ... Litigation Consulting segment to form a single integrated ...
(Date:5/21/2013)... (PRWEB) May 21, 2013 Custom ... to reporting eLearning solution using Tin Can API ... dashboard tool. CLD is a leading developer of ... medical device companies worldwide. , Tin Can ... that helps learners and trainers more accurately measure ...
Breaking Biology Technology:Adult Acne Treatment, Probiotic Action Shares Insight on New Findings Between Probiotics and Heat Tolerance, and What It Means for Acne Sufferers 2Industry Leader John Reynders Joins Moderna Therapeutics as Chief Information Officer 2Industry Leader John Reynders Joins Moderna Therapeutics as Chief Information Officer 3FTI Consulting Releases Realigned Segment Information Reflecting Newly Combined Health Solutions Practice 2CLD Integrates Tin CAN API with its eLearning Solutions and Launches its Excelerometer Tracking Statement Dashboard 2CLD Integrates Tin CAN API with its eLearning Solutions and Launches its Excelerometer Tracking Statement Dashboard 3
... Singapore investigators to coordinate 700 patient trial of ... of head and neck cancer,MISSISSAUGA, ON, Jan. 5 ... TSX:YM, AIM:YMBA), an oncology company that identifies, develops ... announced that the National Cancer Centre of Singapore ...
... Penn Allegheny,Health System and The Western Pennsylvania Hospital announced ... Jones, MD, FACS,and Roger R. Barrette, MD, formerly of ... Drs. Jones and Barrette will direct the ... for the treatment of burn injuries. West Penn,is ...
... the backdrop of a flagging,economy, bailouts, and bleak ... with a future as bright as New Year,s ... market the Embozene(TM),Color-Advanced Microspheres embolization platform for the ... of blood vessels in many,locations) and arteriovenous malformations ...
Cached Biology Technology:YM BIOSCIENCES' NIMOTUZUMAB SELECTED FOR MULTINATIONAL PHASE III TRIAL BY NATIONAL CANCER CENTRE OF SINGAPORE 2YM BIOSCIENCES' NIMOTUZUMAB SELECTED FOR MULTINATIONAL PHASE III TRIAL BY NATIONAL CANCER CENTRE OF SINGAPORE 3YM BIOSCIENCES' NIMOTUZUMAB SELECTED FOR MULTINATIONAL PHASE III TRIAL BY NATIONAL CANCER CENTRE OF SINGAPORE 4West Penn Allegheny Health System Announces Recruitment of Leading Burn Specialists 2West Penn Allegheny Health System Announces Recruitment of Leading Burn Specialists 3First U.S. Implants of Newly Approved Embozene(TM) Color-Advanced Microspheres Embolization Platform 2First U.S. Implants of Newly Approved Embozene(TM) Color-Advanced Microspheres Embolization Platform 3First U.S. Implants of Newly Approved Embozene(TM) Color-Advanced Microspheres Embolization Platform 4
...
... antibody recognizes 30% of IgM-rheumatoid ... It does not cross-react with IgM, ... factor nor with pooled F(Ab)2 fragments. ... ELISA to detect rheumatoid factor. Product ...
...
Salmonella typhimurium Immunogen: Heat inactivated bacterial cells of Salmonella typhimurium B Storage: 4 C...
Biology Products: